SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall , President and CEO, will present at four upcoming investor conferences as follows: H.C. Wainwright 23 rd Annual Global Investment
Company’s ultra-sensitive and quantitative assays support efforts to develop targeted therapies for cancers driven by a variety of genetic mutations SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, will present data
Company has received more than 570,000 samples since launching its COVID-19 testing services in 2020 for skilled nursing homes, businesses, college campuses, health care facilities, and other venues SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Biocept, Inc .
SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present a company overview at the LD Micro Main Event on Wednesday, October 13, 2021 at 11:00
SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15,
Abstract published in the Journal of Molecular Diagnostics shows 200-1,000 times increase in assay sensitivity with the addition of Switch-Blocker technology SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
Revenues for the third quarter of $17.5 million , up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end Robust CNSide™ sequential-quarter volume growth; continued customer base expansion Data generated
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced the presentation of a multi-institutional case
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology.
Biocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect
